Wayne Chester Koff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wayne Chester Koff has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Jaap Goudsmit
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA
2 shared publications- Theodore Schenkelberg
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA
2 shared publications - Aaron Sutherland
La Jolla Institute for Immunology, La Jolla, California, USA
1 shared publication - Adrian B. McDermott
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
1 shared publication - Alba Grifoni
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, USA
1 shared publication - Albert Hofman
Boston, USA
1 shared publication
Latest Publications
- Open Access
- 12 June 2021
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 36 (7) , 753-762
Immune age and biological age as determinants of vaccine responsiveness among elderly populations: the Human Immunomics Initiative research program
The Human Immunomics Initiative (HII), a joint project between the Harvard T.H. Chan School of Public Health and the Human Vaccines Project (HVP), focuses on studying immunity and the predictability of immuneresponsiveness to vaccines in aging populations. This paper describes the hypotheses and methodological approaches of this new collaborative initiative. Central to our thinking is the idea that predictors of age-related non-communicable diseases are the same as predictors for infectious diseases like COVID-19 and influenza. Fundamental to our approach is to differentiate between chronological, biological and immune age, and to use existing large-scale population cohorts. The latter provide well-typed phenotypic data on individuals’ health status over time, readouts of routine clinical biochemical biomarkers to determine biological age, and bio-banked plasma samples to deep phenotype humoral immune responses as biomarkers of immune age. The first phase of the program involves 1. the exploration of biological age, humoral biomarkers of immune age, and genetics in a large multigenerational cohort, and 2. the subsequent development of models of immunity in relation to health status in a second, prospective cohort of an aging population. In the second phase, vaccine responses and efficacy of licensed COVID-19 vaccines in the presence and absence of influenza-, pneumococcal- and pertussis vaccines routinely offered to elderly, will be studied in older aged participants of prospective population-based cohorts in different geographical locations who will be selected for representing distinct biological and immune ages. The HII research program is aimed at relating vaccine responsiveness to biological and immune age, and identifying aging-related pathways crucial to enhance vaccine effectiveness in aging populations.
- 12 June 2021
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 36 (7) , 753-762
Open AccessImmune age and biological age as determinants of vaccine responsiveness among elderly populations: the Human Immunomics Initiative research program
The Human Immunomics Initiative (HII), a joint project between the Harvard T.H. Chan School of Public Health and the Human Vaccines Project (HVP), focuses on studying immunity and the predictability of immuneresponsiveness to vaccines in aging populations. This paper describes the hypotheses and methodological approaches of this new collaborative initiative. Central to our thinking is the idea that predictors of age-related non-communicable diseases are the same as predictors for infectious diseases like COVID-19 and influenza. Fundamental to our approach is to differentiate between chronological, biological and immune age, and to use existing large-scale population cohorts. The latter provide well-typed phenotypic data on individuals’ health status over time, readouts of routine clinical biochemical biomarkers to determine biological age, and bio-banked plasma samples to deep phenotype humoral immune responses as biomarkers of immune age. The first phase of the program involves 1. the exploration of biological age, humoral biomarkers of immune age, and genetics in a large multigenerational cohort, and 2. the subsequent development of models of immunity in relation to health status in a second, prospective cohort of an aging population. In the second phase, vaccine responses and efficacy of licensed COVID-19 vaccines in the presence and absence of influenza-, pneumococcal- and pertussis vaccines routinely offered to elderly, will be studied in older aged participants of prospective population-based cohorts in different geographical locations who will be selected for representing distinct biological and immune ages. The HII research program is aimed at relating vaccine responsiveness to biological and immune age, and identifying aging-related pathways crucial to enhance vaccine effectiveness in aging populations.
- Open Access
Balanced Cellular and Humoral Immune Responses Targeting Multiple Antigens in Adults Receiving a Quadrivalent Inactivated Influenza Vaccine
The role of T cell immunity has been acknowledged in recent vaccine development and evaluation. We tested the humoral and cellular immune responses to Flucelvax®, a quadrivalent inactivated seasonal influenza vaccine containing two influenza A (H1N1 Singapore/GP1908/2015 IVR-180 and H3N2 North Carolina/04/2016) and two influenza B (Iowa/06/2017 and Singapore/INFTT-16-0610/2016) virus strains, using peripheral blood mononuclear cells stimulated by pools of peptides overlapping all the individual influenza viral protein components. Baseline reactivity was detected against all four strains both at the level of CD4 and CD8 responses and targeting different proteins. CD4 T cell reactivity was mostly directed to HA/NA proteins in influenza B strains, and NP/M1/M2/NS1/NEP proteins in the case of the Influenza A strains. CD8 responses to both influenza A and B viruses preferentially targeted the more conserved core viral proteins. Following vaccination, both CD4 and CD8 responses against the various influenza antigens were increased in day 15 to day 91 post vaccination period, and maintained a Th1 polarized profile. Importantly, no vaccine interference was detected, with the increased responses balanced across all four included viral strains for both CD4 and CD8 T cells, and targeting HA and multiple additional viral antigens.
Open AccessBalanced Cellular and Humoral Immune Responses Targeting Multiple Antigens in Adults Receiving a Quadrivalent Inactivated Influenza Vaccine
The role of T cell immunity has been acknowledged in recent vaccine development and evaluation. We tested the humoral and cellular immune responses to Flucelvax®, a quadrivalent inactivated seasonal influenza vaccine containing two influenza A (H1N1 Singapore/GP1908/2015 IVR-180 and H3N2 North Carolina/04/2016) and two influenza B (Iowa/06/2017 and Singapore/INFTT-16-0610/2016) virus strains, using peripheral blood mononuclear cells stimulated by pools of peptides overlapping all the individual influenza viral protein components. Baseline reactivity was detected against all four strains both at the level of CD4 and CD8 responses and targeting different proteins. CD4 T cell reactivity was mostly directed to HA/NA proteins in influenza B strains, and NP/M1/M2/NS1/NEP proteins in the case of the Influenza A strains. CD8 responses to both influenza A and B viruses preferentially targeted the more conserved core viral proteins. Following vaccination, both CD4 and CD8 responses against the various influenza antigens were increased in day 15 to day 91 post vaccination period, and maintained a Th1 polarized profile. Importantly, no vaccine interference was detected, with the increased responses balanced across all four included viral strains for both CD4 and CD8 T cells, and targeting HA and multiple additional viral antigens.
- 19 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 371 (6531) , 759
A universal coronavirus vaccine
COVID-19 has already produced catastrophic social, economic, and public health consequences, with more than 107 million documented cases and 2.3 million deaths. Although this pandemic is far from over, we now have the tools to end it, with the largest and most rapid global deployment of vaccines under way. That we got this far so quickly is remarkable, but next time we might not be so lucky. More virulent and deadly coronaviruses are waiting in the wings. Thus, the world needs a universal coronavirus vaccine.
- 19 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 371 (6531) , 759
A universal coronavirus vaccine
COVID-19 has already produced catastrophic social, economic, and public health consequences, with more than 107 million documented cases and 2.3 million deaths. Although this pandemic is far from over, we now have the tools to end it, with the largest and most rapid global deployment of vaccines under way. That we got this far so quickly is remarkable, but next time we might not be so lucky. More virulent and deadly coronaviruses are waiting in the wings. Thus, the world needs a universal coronavirus vaccine.
- 3 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (579)
Development and deployment of COVID-19 vaccines for those most vulnerable
Ensuring that COVID-19 vaccines are delivered to older populations and those living in low resource settings is essential to end the pandemic.
- 3 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (579)
Development and deployment of COVID-19 vaccines for those most vulnerable
Ensuring that COVID-19 vaccines are delivered to older populations and those living in low resource settings is essential to end the pandemic.
- 30 March 2016
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 15 (10) , 1235-1236
Decoding the human immune system to transform the future of global disease prevention and control
Vaccines have been one of the most effective public health interventions over the last century, preventing and controlling a broad spectrum of infectious diseases [1]. Recent scientific and technol...
- 30 March 2016
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 15 (10) , 1235-1236
Decoding the human immune system to transform the future of global disease prevention and control
Vaccines have been one of the most effective public health interventions over the last century, preventing and controlling a broad spectrum of infectious diseases [1]. Recent scientific and technol...